Sign in

CTOR on Nasdaq

CITIUS ONCOLOGY, INC.

CITIUS ONCOLOGY, INC. is an American pharmaceutical preparations company, incorporated in Delaware.1 It is headquartered in Cranford, New Jersey.1 Its shares trade on Nasdaq under the symbol CTOR.1

Price unavailable

Last updated Oct 21, 2026.

Overview

-$24.8MNet income, fiscal 20252

Compare with another stock.

  • TickerCTOR on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersCranford, New Jersey1
  • Incorporated inDE3
  • Business address11 Commerce Drive, 1St Floor, Cranford, Nj 070163
  • Filer category, Emerging growth company3

See how the biggest companies compare on our leaderboards

(the “Domestication”). As part of the Domestication, TenX changed its name to “Citius Oncology, Inc.” (Nasdaq:4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-55.2%Return on equity2

Financial statements

Operating income52-$23.5M in 2025+16931% since 2022
-$30.0M-$20.0M-$10.0M02022: -$138.1K-$138.1K20222023: -$1.0M-$1.0M2023+633%2024: -$20.6M-$20.6M2024+1931%2025: -$23.5M-$23.5M2025+14%
Net income52-$24.8M in 2025
-$30.0M-$20.0M-$10.0M0$10.0M2022: $380.8K$380.8K20222023: $2.4M$2.4M2023+535%2024: -$21.1M-$21.1M20242025: -$24.8M-$24.8M2025+17%

Every line of the income statement as filed: the last 2 fiscal years, latest first.2

Period ending2025-09-302024-09-30
Research and development$6.4M$4.9M
General and administrative$8.8M$8.1M
Stock-based compensation general and administrative$8.3M$7.5M
Total Operating Expenses$23.5M$20.6M
Operating Loss-$23.5M-$20.6M
Interest income$36.4K
Interest expense-$218.0K
Total Other Income (Expense), Net-$181.7K
Loss before Income Taxes-$23.7M-$20.6M
Income tax expense$1.1M$576.0K
Net Loss-$24.8M-$21.1M
Net Loss Per Share - Basic (in Dollars per share)-$0.34-$0.31
Net Loss Per Share Diluted (in Dollars per share)-$0.34-$0.31
Weighted Average Common Shares Outstanding Basic (in Shares)73.3M shares68.1M shares
Weighted Average Common Shares Outstanding Diluted (in Shares) (in Shares)73.3M shares68.1M shares

Compare CITIUS ONCOLOGY, INC. with another company

Corporate structure

CITIUS ONCOLOGY, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CITIUS ONCOLOGY, INC.

  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on CITIUS ONCOLOGY, INC., latest Aug 14, 2026 (4 filings since Nov 14, 2025)
  • Citius Pharmaceuticals, Inc. Filed SCHEDULE 13D/A on CITIUS ONCOLOGY, INC., latest Jun 4, 2026 (5 filings since Aug 16, 2024)
  • Hudson Bay Capital Management LP Filed SC 13G/A on CITIUS ONCOLOGY, INC., latest Nov 6, 2024 (2 filings since Feb 10, 2023)
  • WOLVERINE ASSET MANAGEMENT LLC Filed SC 13G/A on CITIUS ONCOLOGY, INC., latest Sep 5, 2024 (2 filings since Feb 8, 2024)
  • 10XYZ Holdings LP Filed SC 13D/A on CITIUS ONCOLOGY, INC., latest Aug 15, 2024 (2 filings since Oct 28, 2022)
  • Karpus Management, Inc. Filed SC 13G/A on CITIUS ONCOLOGY, INC., latest Mar 7, 2024 (2 filings since Feb 13, 2024)
  • Mizuho Financial Group Filed SC 13G on CITIUS ONCOLOGY, INC., latest Feb 13, 2024
  • Space Summit Capital LLC Filed SC 13G/A on CITIUS ONCOLOGY, INC., latest Feb 5, 2024 (3 filings since Oct 19, 2022)
  • Lawrence Feis Filed SC 13G/A on CITIUS ONCOLOGY, INC., latest Feb 14, 2023 (3 filings since Oct 20, 2022)
  • CITIUS ONCOLOGY, INC. Cranford, New Jersey

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CITIUS ONCOLOGY, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Inventory

ItemLatestA year beforeChange
Inventory, total$22.3M2 Sep 30, 2025$8.3M2 Sep 30, 2024+169.5%
Work in process$11.7M2 Sep 30, 2025$2.1M2 Sep 30, 2024+448.7%
Finished goods$10.6M2 Sep 30, 2025$6.1M2 Sep 30, 2024+72.4%

Properties, in its own words

Included in the A&R Shared Service Agreement is rent for our portion of the occupancy of offices at 11 Commerce Drive, First Floor, Cranford, New Jersey 07016. The lease is held by Citius Pharma and runs until February 28, 2030.

Item 2 of the 10-K filed Dec 23, 2025.4

Leadership

Who has led CITIUS ONCOLOGY, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Xiaofeng Yuan2022
  2. Leonard L. Mazur2024–now

Chief financial officer

  1. Dahe Zhang2022
  2. Jaime Bartushak2024–now
2025
Board members and other officers (14)

Former names

  • TenX Keane AcquisitionMay 19, 2021 to Aug 5, 20243

Timeline

  1. Sep 29, 20268-K Shareholder vote25
  2. Aug 14, 20268-K Results of operations26
  3. Aug 12, 20268-K Executive or director change27
  4. Aug 5, 20268-K Other events28
  5. Jun 1, 20268-K Other events29
  6. May 15, 20268-K Results of operations30
  7. May 6, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares31
  8. Apr 29, 20268-K Other events32
  9. Apr 28, 20268-K Listing notice or transfer33
  10. Mar 31, 20268-K Other events34
  11. Mar 10, 20268-K Other events35
  12. Mar 4, 20268-K Other events36
  13. Aug 14, 2024New chief executive Leonard L. Mazur becomes CEO10
  14. Oct 13, 2022New chief executive Xiaofeng Yuan becomes CEO11

Calendar

Coming up

  1. Around Nov 13, 2026Next results, estimated About a quarter after its last report. The company hasn't announced the date.

When it reported results

  1. Aug 14, 2026Reported quarterly or annual results26
  2. May 15, 2026Reported quarterly or annual results30
  3. Feb 13, 2026Reported quarterly or annual results37
  4. Dec 23, 2025Reported quarterly or annual results38
  5. Aug 12, 2025Reported quarterly or annual results39
  6. May 14, 2025Reported quarterly or annual results40
  7. Dec 27, 2024Reported quarterly or annual results41

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

257 filings to the SEC since October 2021: 5 annual reports, 12 quarterly reports, 52 major events, 70 insider forms, 24 large holders, 94 other. The latest 20:

  1. Sep 29, 20268-K CURRENT REPORT EDGAR
  2. Aug 26, 2026ARS EDGAR
  3. Aug 26, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
  4. Aug 14, 20263 PRIMARY DOCUMENT EDGAR
  5. Aug 14, 2026424B3 PROSPECTUS EDGAR
  6. Aug 14, 202610-Q QUARTERLY REPORT EDGAR
  7. Aug 14, 20268-K CURRENT REPORT EDGAR
  8. Aug 14, 2026SCHEDULE 13G/A EDGAR
  9. Aug 12, 20268-K CURRENT REPORT EDGAR
  10. Aug 5, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  11. Aug 5, 20268-K CURRENT REPORT EDGAR
  12. Jun 5, 2026EFFECT EDGAR
  13. Jun 4, 2026SCHEDULE 13D/A EDGAR
  14. Jun 3, 2026CORRESP EDGAR
  15. Jun 3, 2026UPLOAD EDGAR
  16. Jun 1, 2026424B3 EDGAR
  17. Jun 1, 20268-K CURRENT REPORT EDGAR
  18. May 29, 2026DEF 14C DEFINITIVE INFORMATION STATEMENT EDGAR
  19. May 29, 2026S-3 REGISTRATION STATEMENT EDGAR
  20. May 22, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR

The 257 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Leonard Mazur81$166.2K$3.8M51
2025Myron Holubiak79$450.0K$2.2M51
2025Myron Czuczman66$225.0K$2.0M51
2024Chief Executive Officer and Executive Chairman$166.2K$2.2M51
2024Executive ViceChairman$450.0K$1.3M51
2024Chief Medical Officer$225.0K$995.0K51

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Armistice Capital, LLC8,705,589$5.7M0.2%−483,266
Bank Of America Corp /de/3,835,160$2.5M0.0%No change
Vanguard Capital Management LLC546,325$355.1K0.0%+11,501
UBS Group AG334,619$217.5K0.0%+297,779
Geode Capital Management, LLC245,407$159.5K0.0%−19,326
Vanguard Fiduciary Trust Co121,910$79.2K0.0%No change
IFP Advisors, Inc107,424$69.8K0.0%No change
Citadel Advisors LLC90,586$58.9K0.0%New
Northern Trust Corp45,746$29.7K0.0%No change
State Street Corp42,900$27.9K0.0%No change
XTX Topco Ltd20,638$13.4K0.0%New
Tower Research Capital LLC (TRC)13,816$9.0K0.0%New
Arkadios Wealth Advisors11,666$7.6K0.0%No change
Osaic Holdings, Inc.1,000$6500.0%−9,125
Wells Fargo & Company/mn500$3250.0%New
Barclays PLC90$590.0%New
Morgan Stanley23$150.0%New
Virtu Financial LLC21,877$140.0%New
Caitong International Asset Management Co., Ltd1$10.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How CITIUS ONCOLOGY, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCITIUS ONCOLOGY, INC.1
  • CIK0001851484
  • Employer ID (EIN)99-43626604
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsSeptember 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address11 Commerce Drive, 1St Floor, Cranford, NJ 070161
  • Mailing address11 Commerce Drive, First Floor, Cranford, NJ 070161
  • Phone(908) 967-66771
  • Shares outstanding92,981,204 as of Aug 13, 20267
  • Public float$5.1M as of Mar 31, 20254
  • AuditorWolf & Company, P.C., Boston, Massachusetts PCAOB ID 392; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceMay 19, 20211
  • Filings265 in all: 8-K (51), 4 (30), 4/A (24), CORRESP (18), 3 (16), 10-Q (12), UPLOAD (12), 424B3 (9)1
    All 43 form types

    S-1/A (9), EFFECT (7), SC 13G/A (7), SC 13G (6), 425 (5), S-4/A (5), 10-K (4), SCHEDULE 13D/A (4), DEF 14A (3), DEF 14C (3), NT 10-Q (3), PRE 14C (3), S-3 (3), SCHEDULE 13G/A (3), 424B4 (2), 424B5 (2), DRS (2), NT 10-K (2), S-1 (2), SC 13D (2), SEC STAFF LETTER (2), 10-K/A (1), 25-NSE (1), 8-A12B (1), 8-K/A (1), ARS (1), CERT (1), DEFA14A (1), DEFA14C (1), POS AM (1), PRE 14A (1), S-4 (1), S-8 (1), SC 13D/A (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Dec 23, 2025
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Aug 26, 2026
    Latest 8-K (8-K) Sep 29, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareCTORNASDAQ

From the cover page of the 10-K filed Dec 23, 2025 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks CITIUS ONCOLOGY, INC. names in Item 1A of its 10-K filed Dec 23, 2025: 52 risks under these headings, as written.4

  • If any of the following risks, or other risks not presently known to us or that we currently believe to not be significant, develop into actual events, then our business, financial condition, results of operations or prospects could be materially adversely affected. If that happens, the market price of our securities could decline, and stockholders may lose all or part of their investment.
  • Risks Related to Our Financial Position and Need for Additional Capital
  • Our independent registered public accounting firm’s report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern.
  • We require substantial additional funding in the near future to support our operations, complete the commercialization of LYMPHIR, which may not be available on acceptable terms, or at all.
  • We have a history of net losses and expect to incur losses for the foreseeable future. We may never generate revenues or, if we are able to generate revenues, achieve profitability.
  • Our ongoing exploration of alternative strategic paths may not result in entering into or completing transactions, when necessary, and the process of reviewing alternative strategic paths or their conclusion could adversely affect our stock price.
  • In the event we do not successfully complete a strategic transaction, should this be deemed necessary, our Board may decide to pursue a dissolution and liquidation of our Company. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.
  • Risks Related to Our Business and Our Industry
  • We have one approved product and have an unproven business strategy and may never achieve successful commercialization of LYMPHIR or any future product candidates or achieve or maintain profitability.
  • We have a limited operating history upon which to evaluate our ability to successfully commercialize LYMPHIR and any future product candidate.
  • We are and may be required to make milestone payments to the licensor and former licensee of the LYMPHIR intellectual property in connection with our development and commercialization of LYMPHIR, which could adversely affect the profitability of LYMPHIR.
  • A material breach or default under any of our license agreements, including failure to make timely payments when due, gives the licensor party to such agreement the right to terminate the license agreement, which termination would materially harm our business.
The other 42 risks
  • We rely exclusively on third parties to formulate and manufacture our product candidates. Our failure to abide by our contractual obligations with these third parties, including timely payment, could result in a delay or the loss of necessary third-party support.
  • We face significant risks in our commercialization efforts of LYMPHIR and development of any future product candidate.
  • LYMPHIR may not gain market acceptance among physicians, patients, healthcare payers or the medical community and may not generate significant revenue.
  • We will not be able to create a market for LYMPHIR or any future product candidate if we fail to establish marketing, sales, and distribution capabilities.
  • Our projections regarding the market opportunity for our LYMPHIR may not be accurate, and the actual market for LYMPHIR may be smaller than we estimate.
  • Our ability to generate product revenues will be diminished if LYMPHIR, or any of our future product candidates that may be approved, sells for inadequate prices or patients are unable to obtain adequate levels of reimbursement.
  • The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
  • The markets in which we operate are highly competitive and we might be unable to compete successfully against new entrants or established companies.
  • Healthcare reform measures could hinder or prevent LYMPHIR’s commercial success, or any of our future product candidates that may be approved.
  • Any termination, or breach by, or conflict with our strategic partners could harm our business.
  • We rely on the significant experience and specialized expertise of our executive management and other key personnel and the loss of any of our executive management or key personnel or our inability to successfully hire their successors could harm our business.
  • If we are unable to retain or hire additional qualified personnel, our ability to grow our business might be harmed.
  • We expect to need to increase the size of our organization to further develop our product candidates, and we may experience difficulties in managing growth.
  • We are subject to information technology and cyber-security threats which could have an adverse effect on our business and results of operations.
  • The results of pre-clinical studies and completed clinical trials are not necessarily predictive of future results, and our current and any future product candidates may not have favorable results in later studies or trials.
  • Risks Related to Our Regulatory and Legal Environment
  • Following the regulatory approval of LYMPHIR, we remain subject to ongoing regulatory obligations and restrictions, which may result in significant expense and limit our ability to commercialize LYMPHIR and any future approved products.
  • We could be forced to pay substantial damage awards if product liability claims that may be brought against us are successful.
  • We might not obtain the necessary U.S. or foreign regulatory approvals to commercialize any future product candidates.
  • Risks Related to Our Intellectual Property
  • Our business depends on protecting our intellectual property.
  • We rely on trade secret protections through confidentiality agreements with our employees and other parties, and the breach of these agreements could adversely affect our business and prospects.
  • If we infringe the rights of third parties we might have to forego developing and/or selling any approved products, pay damages, or defend against litigation.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition and our business, financial condition and results of operations may be adversely affected.
  • Risks Related to Our Common Stock
  • The market price of our common stock is highly volatile, and you may lose some or all of your investment.
  • Future sales of a substantial number of shares of our common stock may cause the price of our common stock to decline.
  • You may experience dilution of your ownership interests because of the future issuance of additional shares of common stock or securities convertible into common stock.
  • Substantial sales of our common stock may occur in connection with the potential distribution of shares by Citius Pharma, which could cause our stock price to decline.
  • If we fail to meet the Nasdaq continued listing requirements, it could result in a suspension or delisting of the common stock.
  • If our common stock were delisted and determined to be a “penny stock,” a broker-dealer may find it more difficult to trade the common stock and an investor may find it more difficult to acquire or dispose of the common stock in the secondary market.
  • Our Certificate of Incorporation allows for our Board to create new series of preferred stock without further approval by our stockholders, which could adversely affect the rights of the holders of the common stock.
  • We have not paid cash dividends in the past and we do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the capital appreciation, if any, of our common stock.
  • Our operating results may fluctuate significantly.
  • If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse opinion regarding our common stock, our stock price and trading volume could decline.
  • We are a controlled company within the meaning of the Nasdaq continued listing requirements and, as a result, will qualify for, and may rely on, exemptions from certain corporate governance requirements. Our stockholders may not have the same protection afforded to stockholders of companies that are subject to such governance requirements.
  • Volatility in our share price could subject us to securities litigation.
  • Provisions in our Certificate of Incorporation, Bylaws and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.
  • We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our shares less attractive to investors.
  • If our estimates or judgments relating to our critical accounting policies prove to be incorrect or financial reporting standards or interpretations change, the Company’s results of operations could be adversely affected.
  • Conflicts of interest may arise from our relationship with Citius Pharma.
  • Certain of our directors and officers may have actual or potential conflicts of interest because of their positions with Citius Pharma.
  • Citius Pharma currently performs or supports many of our important corporate functions, which would be difficult to replace if Citius Pharma were to cease providing and we are obligated to pay to Citius Pharma the fees for services under the A&R Shared Services Agreement and must repay the principal due on a promissory note issued in August 2024.
  • Our financial statements may not necessarily be indicative of the conditions that would have existed if we had been operated as an unaffiliated company of Citius Pharma.
  • We are controlled by Citius Pharma, whose interests may differ from those of public stockholders.

Legal proceedings

We are not involved in any litigation that we believe could have a material adverse effect on our financial position or results of operations. There is no action, suit, proceeding, inquiry, or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of our executive officers, threatened against or affecting our Company or our officers or directors in their capacities as such.

In the future, we might from time to time become involved in litigation relating to claims arising from our ordinary course of business.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
    SEC EDGAROther events
  29. 29
    SEC EDGAROther events
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
    SEC EDGAROther events
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51